CSL Vifor
https://www.csl.com/we-are-csl/our-businesses-and-products/csl-vifor
8952 Schlieren, Zürcherstrasse 39D
+41 58 851 80 00
Pioneer in iron-based therapies, CSL Vifor is a global leader in iron deficiency and iron deficiency anaemia therapies, with a history dating back to 1872, when pharmacist Caspar Friedrich Hausmann opened a pharmacy in St. Gallen, Switzerland. Since then, we have proven our ability to identify and serve therapeutic areas and patients with significant unmet medical need. Building on our heritage and expertise in iron deficiency therapy, and together with our joint company Vifor Fresenius Medical Care Renal Pharma, today we have a strong and rapidly growing presence in nephrology, and we are committed to launching the next generation of therapies to truly address the full spectrum of kidney disease.
CSL Vifor
Zürcherstrasse 39D
8952 Schlieren
143 Ergebnisse für "lead" unter CSL Vifor
LEAD Grants | CSL
... LEAD Grants Local Empowerment for Advocacy Development No one knows their condition and the ... for better care. We offer a unique advocacy program, called LEAD Grants, that help at the patient ... LEAD Grants | CSL ... https://www.csl.com/patients-public-health/patient-support-and-organizations/ lead-grants ... LEAD Grants | CSL ...
About FlippingBook for Ebooks
... campaigns. What’s more, any ebook created with FlippingBook will gather leads for you with a built-in lead ... how exactly each lead interacts with your content with in-depth analytics, native to FlippingBook ... gather leads for you with a built-in lead capture form. Collect your prospects’ email addresses, names ... , phone numbers, and more. You can also see how exactly each lead interacts with your content with in ...
Roche Glycart AG
https://www.roche.ch/en/sites/schlieren
8952 Schlieren, Wagistrasse 10
+41 43 215 10 00
The mission of the Roche Innovation Center Zurich (RICZ) is to be a leader in developing new generations of engineered antibody products with increased efficacy that address unmet clinical needs. The RICZ site is also the Center of Excellence in Cancer Immunotherapy within the Roche Group.
Roche Glycart AG
Wagistrasse 10
8952 Schlieren
356 Ergebnisse für "lead" unter Roche Glycart AG
How to Lead an ABS Committee Effectively
... to Lead an ABS Committee Effectively Most hospital ABS committees include a multidisciplinary team ... How to Lead an ABS Committee Effectively ... https://lableaders.roche.com/us/en/resource-center-pages/2110-how-to- lead-an-abs-committee ... How to Lead an ABS Committee Effectively ...
How to lead an ABS committee effectively
... to lead an ABS committee effectively Most hospitals go to great lengths to include professionals from ... together in the first place, Dr. Tran notes. Lead from behind In his opinion, says Edward Septimus, MD ... How to lead an ABS committee effectively ... https://lableaders.roche.com/global/en/articles/how-to- lead-an-abs-committee-effectively-2110.html ... How to lead an ABS committee effectively ...
University of Zurich
https://www.campus-schlieren.uzh.ch/en.html
8952 Schlieren, Wagistrasse 12
The University of Zurich (UZH) is Switzerland’s largest university, with seven faculties and a current enrollment of over 26,000 students. More than 5,000 highly qualified members of the teaching staff, including some 580 professors, teach and conduct research at the 150 University institutes. In the field of life sciences, the University of Zurich is well known for its groundbreaking research in medicine, immunology, neuroscience, and structural biology. In the interest of serving the community, the University of Zurich promotes the transfer of research-based knowledge to private enterprise, and our spin-off ventures and business partnerships regularly lead to the creation of attractive jobs in innovative fields.
University of Zurich
Wagistrasse 12
8952 Schlieren
1474 Ergebnisse für "lead" unter University of Zurich
UZH - CRPP radiz - Rare Disease Initiative Zurich - Lead and coordi...
... Matthias R. Baumgartner, Prof. Dr. med. Lead radiz University of Zurich Phone: +41 44 266 77 22 ... UZH - CRPP radiz - Rare Disease Initiative Zurich - Lead and coordination ... UZH - CRPP radiz - Rare Disease Initiative Zurich - Lead and coordination Home Main navigation ... UZH - CRPP radiz - Rare Disease Initiative Zurich - Lead and coordination ...
UZH - URPP Dynamics of Healthy Aging - Memory training doesn't lead...
... Breadcrumb Memory training doesn't lead to a general increase in cognitive performance URPP ... UZH - URPP Dynamics of Healthy Aging - Memory training doesn't lead to a general increase in ... UZH - URPP Dynamics of Healthy Aging - Memory training doesn't lead to a general increase in ... UZH - URPP Dynamics of Healthy Aging - Memory training doesn't lead to a general increase in ...
ETH Entrepreneurship
https://ethz.ch/en/industry/entrepreneurship.html
8952 Schlieren, Wagistrasse 18
Excellence in entrepreneurship at ETH Zurich is driven by world-class research and education. It gives rise to groundbreaking new ventures that consolidate Switzerland’s technological leadership. Are you an aspiring entrepreneur seeking to find solutions to global challenges and create a better future for humanity. Or are you just interested in the entrepreneurial ecosystem at ETH Zurich? Browse our websites to find out more or reach out to the Entrepreneurship group, if you have any questions.
ETH Entrepreneurship
Wagistrasse 18
8952 Schlieren
1667 Ergebnisse für "lead" unter ETH Entrepreneurship
Dataset for the article "Room-Temperature, Highly Pure Single-Photo...
... Lead ... Lead Halide Perovskite Quantum Dots" - Research Collection Header Upper Right Menu Log in de Research ... Lead ...
[ACS Nano] Exploration of Near Infrared-Emissive Colloidal Multinar...
... Hybrid organic–inorganic and fully inorganic lead halide perovskite nanocrystals (NCs) have recently ... [ACS Nano] Exploration of Near Infrared-Emissive Colloidal Multinary Lead Halide Perovskite ... -colloidal-multinary- lead-halide-perovskite-nanocrystals-using-an-automated-microfluidic-platform.html ... [ACS Nano] Exploration of Near Infrared-Emissive Colloidal Multinary Lead Halide Perovskite ...
Bio-Technopark Schlieren-Zürich
8952 Schlieren, Wagistrasse 23
+41 76 336 99 44
mario.jenni@bio-technopark.ch
The Bio-Technopark offers professional support for life science start-ups in the setting up and expansion of business activities and promotes interaction between start-ups, academia and industry. A nationally and internationally respected science park has grown up at Schlieren. Through stringent selection, coaching and support, more than 30 successful start-up companies with 750 employees are located here. Eight have been acquired by large corporates, but are still active in the park. Together with 20 institutes and clinics from the University and University Hospital Zurich, an innovative mix of very young and well-established companies and academic research groups has emerged.
Bio-Technopark Schlieren-Zürich
Wagistrasse 23
8952 Schlieren
35 Ergebnisse für "lead" unter Bio-Technopark Schlieren-Zürich
Molecular Partners Provides Additional Details on Clinical Studies ...
... News Molecular Partners Provides Additional Details on Clinical Studies of Proprietary Lead ... in the phase 2 multiple myeloma study of its lead oncology asset MP0250. In the first phase 2 study ... Molecular Partners Provides Additional Details on Clinical Studies of Proprietary Lead Oncology ... -studies-of-proprietary- lead-oncology-asset-mp0250/ ... Molecular Partners Provides Additional Details on Clinical Studies of Proprietary Lead Oncology ...
Virometix Closes Financing Round › BIO-TECHNOPARK® Schlieren-Zürich
... , including the start of a phase 1 clinical study for its lead vaccine V306 for RSV, which has shown excellent ... phase 1 clinical study for its lead vaccine V306 for RSV, which has shown excellent safety and strong ...
Somagenetix
https://www.wysszurich.ch/projects/somagenetix
8952 Schlieren, Wagistrasse 23
Gene therapy solutions for patients with severe inherited diseases.
Somagenetix
Wagistrasse 23
8952 Schlieren
1939 Ergebnisse für "lead" unter Somagenetix
Intraoperative Neurophysiologic Assessment in Deep Brain Stimulatio...
... its Impact on Lead Placement Krauss, Philipp ; Oertel, Markus Florian ; Baumann-Vogel, Heide ; Imbach ... ). Intraoperative Neurophysiologic Assessment in Deep Brain Stimulation Surgery and its Impact on Lead Placement ... Intraoperative Neurophysiologic Assessment in Deep Brain Stimulation Surgery and its Impact on Lead ... Intraoperative Neurophysiologic Assessment in Deep Brain Stimulation Surgery and its Impact on Lead ... Intraoperative Neurophysiologic Assessment in Deep Brain Stimulation Surgery and its Impact on Lead ...
Dust and grit matter: abrasives of different size lead to opposing ...
... Dust and grit matter: abrasives of different size lead to opposing dental microwear textures in ... Dust and grit matter: abrasives of different size lead to opposing dental microwear textures in ... Dust and grit matter: abrasives of different size lead to opposing dental microwear textures in ... Dust and grit matter: abrasives of different size lead to opposing dental microwear textures in ...
Neurimmune Therapeutics AG
8952 Schlieren, Wagistrasse 18
+41 44 755 46 46
info@neurimmune.com
Neurimmune is a biopharmaceutical company dedicated to the development of immunotherapeutics for the treatment and prevention of human disorders with a focus on protein aggregation diseases.
Neurimmune Therapeutics AG
Wagistrasse 18
8952 Schlieren
68 Ergebnisse für "lead" unter Neurimmune Therapeutics AG
Neurimmune - 12.09.2018: Neurimmune appoints Christoph Hock as Chie...
... September 12, 2018 Neurimmune appoints Christoph Hock as Chief Medical Officer to lead clinical ... August 2018 to the newly created position of Chief Medical Officer (CMO) in order to lead clinical ... Neurimmune - 12.09.2018: Neurimmune appoints Christoph Hock as Chief Medical Officer to lead ... -officer-to- lead-clinical-development.html ... Neurimmune - 12.09.2018: Neurimmune appoints Christoph Hock as Chief Medical Officer to lead ...
Neurimmune - Product Pipeline
... Product Pipeline Neurimmune’s early pipeline is filled with a number of exciting lead candidates ... pipeline is filled with a number of exciting lead candidates for unmet medical needs. Our recombinant human ... experts in these fields. Download PDF Therapeutic Area Indication Target Partner Drug Hit selection Lead ...
GlycoEra AG
8820 Wädenswil, Einsiedlerstrasse 34
+41 44 733 85 75
info@glycoera.com
GlycoEra AG is advancing glycoengineered therapeutics to address unmet medical needs. Despite significant advancements in understanding the role of glycans in human health and diseases, this knowledge has not translated well into therapeutic drug development, a consequence of the limitations and complexities of controlling glycosylation processes. GlycoEra’s platform has overcome these challenges! The CustomGlycan Platform enables glycan-mediated modes of action through the engineering of highly defined specific glycan structures, accessing a novel combinatorial dimension for the treatment of very challenging diseases.
GlycoEra AG
Einsiedlerstrasse 34
8820 Wädenswil
4 Ergebnisse für "lead" unter GlycoEra AG
Pipeline – GlycoEra
... Applications & Pipeline Lead indications chosen based on validated targets GlycoEra selected ... attractiveness were the criteria used to select lead indications. GlycoEra Pipeline Autoimmune therapeutics G ... Lead indications chosen based on validated targets GlycoEra selected indications based on ... criteria used to select lead indications. GlycoEra Pipeline Autoimmune therapeutics G-LyTAC for autoimmune ...
Microsoft Word - GlycoEra_CSO_Press Release_FINAL.docx
... autoimmune diseases, inflammation, and oncology, among others. He will lead GlycoEra’s efforts to develop ... lead generation, optimization, pharmacology, and translational research will serve GlycoEra well as we ... autoimmune diseases, inflammation, and oncology, among others. He will lead GlycoEra’s efforts to develop ... lead generation, optimization, pharmacology, and translational research will serve GlycoEra well as we ...
Dinaqor
8952 Schlieren, Wagistrasse 25
DiNAQOR’s mission is to develop gene therapy solutions that transform the lives of patients with heart disease. Our novel and innovative gene therapy platform is focused on advancing treatments for patients affected by genetic cardiomyopathies, a disease of the heart muscle that can lead to heart failure.
Dinaqor
Wagistrasse 25
8952 Schlieren
43 Ergebnisse für "lead" unter Dinaqor
Viral Vector Supply – DiNAQOR
... , our lead preclinical program for patients affected by MYBPC3-linked cardiomyopathy. © Copyright 2021 ... , clinical and commercial production support for DiNA-001, our lead preclinical program for patients affected ...
Viral Vector Supply – DiNAQOR
... , our lead preclinical program for patients affected by MYBPC3-linked cardiomyopathy. © Copyright 2021 ... preclinical, clinical and commercial production support for DiNA-001, our lead preclinical program for ...
Topadur Pharma AG
8952 Schlieren, Grabenstrasse 11a
A team dedicated to develop innovative speciality medication for the treatment of severe wound-healing problems enabling significant improvements of patients quality of life. TOPADUR’s lead R&D programs are local active, highly potent, dual mode of action drugs. TOPADUR’s unique development candidates #3;work on validated drug targets resulting in higher than average clinical success chances.
Topadur Pharma AG
Grabenstrasse 11a
8952 Schlieren
8 Ergebnisse für "lead" unter Topadur Pharma AG
Presentation | Topadur
... and anti-fibrotic effects Topadur’s lead R&D proprietary programs are local active, highly potent ... -fibrotic effects Topadur’s lead R&D proprietary programs are local active, highly potent, dual mode of ...
News
... a patent covering the lead drug candidate, TOP-N53 used for the treatment of chronic wounds ... -N53 The European Patent Office granted a patent covering the lead drug candidate, TOP-N53 used for the ...